Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.

AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy.

Make plans to attend the AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy, taking place February 14-17, 2018 in San Diego, CA.

The collaborative meeting program will allow you to connect directly with the profession's foremost experts on the latest topics in Molecular Imaging in Cancer Biology and Therapy, including:

  • Emerging Advances in Imaging Technologies
  • Novel Ligands and Target Identification
  • Imaging Cancer Immunotherapy I: Cell-Based Therapies
  • Imaging Cancer Immunotherapy II: Checkpoint Blockade, Resistance, and Targeted Therapies
  • Early Detection of Cancer: Liquid Biopsies and Imaging
  • Pathways for Clinical Translation: Novel Agents and Strategies
  • Modeling Cancer: In Silico, In Vitro, In Vivo
  • Optics in the Oncology Surgical Suite
  • Super-resolution imaging of cancer biology and metastasis
  • Imaging Cancer Metabolism

View the educational program | Register online

Coding and Reimbursement

The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.

For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.

For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.

Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!

Dose Optimization

In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.

SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.



The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.

View Guidelines.

Focusing on the Future of Molecular Imaging

SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.

Access resources.

The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.

Educational Offerings

SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors. 

Visit the SNMMI Learning Center.

Additional Resources

  • March 23, 2018Partial Relief for High-Value Radiopharmaceuticals in Signed Budget Bill

    Buried in the Budget Bill that was just signed into law is a provision that provides some high-value radiopharmaceuticals partial and temporary relief. It also mandates that the Government Accountability Office study the problems with reimbursement for these drugs and report back to Congress.
    (Government Relations News)

  • March 22, 2018Societies Collaborate to Address Differentiated Thyroid Cancer

    Representatives of SNMMI, the European Association of Nuclear Medicine (EANM), the European Thyroid Association (ETA) and American Thyroid Association (ATA) met at the Multilateral Conference on Differentiated Thyroid Cancer and began working collaboratively on issues related to the care of patients with thyroid cancer, with particular focus on radioactive iodine (RAI) therapy.
    (SNMMI News)

  • March 21, 2018SNMMI Seeks Expanded Coverage for NaF PET

    SNMMI, the World Molecular Imaging Society (WMIS), and the American College of Radiology (ACR) are recommending that the Centers for Medicare and Medicaid Services (CMS) reconsider the current restrictive coverage policy for NaF PET imaging to identify bone metastases, which can inform treatment strategy.
    (Government Relations News)

  • March 15, 2018Patient Fly-In for Capitol Hill Advocacy: Bill to Reclassify Diagnostic Radiopharmaceuticals as Drugs

    Patients advocates with a wide range of health conditions—including neuroendocrine tumors, lymphoma and cancers of the lung, breast, and prostate—flew into Washington, DC, for March 14 meetings on Capitol Hill to urge support for a bill that would require the Centers for Medicare & Medicaid Services (CMS) to reclassify diagnostic radiopharmaceuticals as drugs. Patients rely on the radiopharmaceuticals for diagnosing and monitoring their conditions, as well as guiding therapy.
    (Government Relations News)


Call for Abstracts!

Present Your Research. Increase Your Professional Recognition. 

Distinguish yourself from your peers and earn the opportunity to present your original research to an international audience of leading nuclear medicine and molecular imaging professionals at the SNMMI 2018 Annual Meeting, June 23-26, 2018 in Philadelphia, Pennsylvania, USA. 

Submit your abstract.

Abstract submission deadline: January 9, 2018

Featured Resources